Management Team & Co-Founders

Lisa Padilla, CEO & Co-Founder

Business/Tax Attorney, Angel Investor, Boston University, BS, LLM; Suffolk University, JD; Callen Lorde Community Health Center Board Member 2014 – Present (Audit, Finance and By-Laws Committees)

Dr. Alison Lukacsko, CSO & Co-Founder

VP, GM and VP of Innovation, Research & Development, Georgia-Pacific, LLC; VP Business Development & R&D, Church & Dwight; Sr. Director and R&D Director Bristol-Myers Squibb (including women’s health)

Allison Drew Klein, Director of Community Relations & Co-Founder

Pitney Bowes (30+ years, sales), Angel Investor

Beryl Health – Human Applications

Roland Baron, DMD, PhD

SAB Chair (Beryl Health), Professor Dept. of Medicine and Chair of the Dept. of Oral Medicine, Infection, and Immunity, Harvard University

Felicia Cosman, MD

Clinical scientist, osteoporosis specialist, endocrinologist, Prof. of Medicine Columbia University Medical School, & North American Co-Editor in Chief of Osteoporosis International. She investigated cyclic, combination & sequential regimens of teriparatide and antiresorptive agents; evaluated teriparatide’s effect on bone formation (human femur); lead contributor to pivotal studies of abaloparatide and romosozumab.

Javier San Martin, MD

Former lead clinical development in bone, osteoporosis (Lilly, Amgen) and in rare diseases former lead for the development of FGF23 antibodies for XLH at Ultragenyx

Yankel Gabet, DMD

Director of Research, Bone Laboratory at Tel Aviv University

Beryl Therapeutics – Veterinary Applications

Cecilia Hillard PhD

SAB Chair, Associate Dean for Research; Professor; Director, Neuroscience Research Center at Medical College of Wisconsin

Nicole Ehrhart, VMD

MS, DACVS, ACVS Founding Fellow, Surgical Oncology, Director of the Columbine Health Systems Center for Healthy Aging

© 2020 to 2025 by Beryl Therapeutics Inc. All Rights Reserved.